Efficacy News and Research

RSS

UTSA researchers develop bait pellets to combat Lyme disease

A breakthrough in the fight against Lyme disease is moving from the laboratory to the hardware store.

30 Jun 2026

Achieve precise, noncontact tissue ablation at low power levels

445 nm diode lasers have already been used successfully and safely for cholesteatoma surgery.

30 Jun 2026

New drug candidate reduces toxic protein clumps of Huntington's disease

An experimental drug has been shown to alleviate symptoms of Huntington's disease and extend lifespan in mouse models. Further studies are required to determine whether these results may also apply to humans.

29 Jun 2026

Scaling organoid workflows with automation and AI for drug discovery

Discover how automation, AI, and organoid technologies are improving drug discovery through scalable workflows.

From Molecular Devices UK Ltd 29 Jun 2026

Simple blood test could identify the most effective obesity drug

Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, enhancing personalized therapy.

29 Jun 2026

Nasal viruses may drive allergic rhinitis, and ribavirin shows early promise as a targeted spray treatment

Nasal commensal viruses may worsen allergic rhinitis by activating type I IFN-linked neutrophils and NET formation. Ribavirin reduced nasal viral abundance and improved symptoms in mice and in a small phase 2 trial.

28 Jun 2026

Scientists uncover immune mechanisms driving rare gastrointestinal disorder

A collaborative team led by Dr. Jingnan Li and Dr. Ji Li at Peking Union Medical College Hospital, together with Associate Professor Xiaohuan Guo at Tsinghua University and Academician Ye-Guang Chen at Tsinghua University School of Life Sciences, published a study in Volume 2, article number 28 of the journal Immunity & Inflammation on June 17, 2026.

26 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Researchers develop novel strategy to selectively target tumor microenvironments

A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR and other kinases with controlled release in tumor microenvironments to improve therapeutic efficacy, with promising results.

25 Jun 2026

Natural bioactive compounds target miR-29a molecule to prevent cancer development

A study published in Current Molecular Pharmacology provides a comprehensive analysis of microRNA-29a (miR-29a) as a pivotal regulator in cancer development, and examines how natural bioactive compounds may offer a promising strategy for cancer prevention by modulating its expression.

25 Jun 2026

New review highlights TREM-1 receptor as target for inflammatory diseases

A comprehensive review recently published in Current Molecular Pharmacology consolidates the growing evidence surrounding the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a central amplifier of innate immune responses and a promising therapeutic target for a range of inflammatory diseases.

25 Jun 2026

AI-driven approach identifies promising new target for CAR T cell therapy

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that firmly centers scientists' expertise to find viable target antigens for CAR T cell therapy.

25 Jun 2026

European project receives €15 million to study phage-based therapies

Bacteria are becoming increasingly resistant to antibiotics. One alternative is treatment with viruses that exclusively infect bacteria, known as phages.

25 Jun 2026

FDA approves palbociclib combination for advanced HR-positive HER2-positive breast cancer

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment.

24 Jun 2026

Functional brain imaging can help guide accelerated TMS for depression

Mass General Brigham study suggests that functional brain imaging can help guide accelerated transcranial magnetic stimulation for depression.

24 Jun 2026

Microbes trigger cell death to boost cancer immunotherapy effectiveness

Traditional cancer treatments like chemotherapy and radiotherapy can induce immunogenic cell death (ICD), but their efficacy is often limited by drug resistance, severe off-target toxicity, and immune-related adverse events.

24 Jun 2026

Engineered CAR-T cells offer potential rheumatoid arthritis cure

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a reality that new research from Tsinghua University may soon begin to change.

22 Jun 2026

New vaccines successfully boost frontline immune cells against HIV

T-cells are the immune system's frontline defenders with a crucial role in controlling HIV. In a milestone clinical trial published in the Journal of Clinical Investigation, researchers with the UNC Institute for Global Health and Infectious Diseases (IGHID) at the UNC School of Medicine have demonstrated that new vaccines can significantly boost T cells targeting the most vulnerable, conserved regions of HIV-areas considered key to effective immune control.

22 Jun 2026

Study shows positive milestones shape the lives of youth

Which major life events matter to young people? A recent study by the University of Zurich (UZH) shows that adolescents and young adults primarily cite positive, everyday developmental steps as formative events, for example school and apprenticeships, friendships, first relationships, travel and moving out of their parents' home.

22 Jun 2026